1 results
3 - The Regulatory and Ethical Challenges of Pediatric Research
-
- By M. Dianne Murphy, Director of the Office of Pediatric Therapeutics, FDA's Office of the Commissioner, Sara F. Goldkind, Bioethicist, Office of Pediatric Therapeutics within the Office of the Commissioner of the Food and Drug Administration
- Michael A. Santoro, Rutgers University, New Jersey, Thomas M. Gorrie
-
- Book:
- Ethics and the Pharmaceutical Industry
- Published online:
- 04 December 2009
- Print publication:
- 31 October 2005, pp 48-67
-
- Chapter
- Export citation
-
Summary
By the 1970s, the American Academy of Pediatrics (AAP) and the Food and Drug Administration (FDA) had publicly stated that the same level of scientific investigation required before a product is marketed for adults should be required for pediatric therapies. We entered the twenty-first century with hundreds of exciting new therapies, studied and approved for use in adults, that were being used in pediatrics without even the most fundamental of studies. Studies of absorption, distribution, metabolism, and elimination (ADME) and clinical trials were not conducted in the pediatric population. Most pediatric dosing calculations were done on a weight-based metric derived from adult dosing recommendations. It is counterintuitive that a society would demand strict controls on product development for the more physiologically mature and stable organism – the adult – and simultaneously ignore the need for scientific data to guide therapeutic use in the more complex and physiologically evolving and developing pediatric population. This was the situation, however, toward the end of the twentieth century. This chapter describes (1) the regulatory changes that opened the gateway to pediatric trials; (2) parameters for the disclosure of trial results; (3) scientific information gleaned from pediatric trials; (4) pediatric safety concerns; and (5) ethical considerations in pediatric research.
Pediatric research: the challenge to governments
It is an unfortunate truth that children not only are the therapeutic orphans described by Dr. H. Shirkey in 1963, but also are often the “sentinel canaries” in the mine of pharmaceutical therapeutics.